Covid-19, an antiviral treatment from Pfizer

The United States has signed two contracts worth around $1 billion for an order for the COVID-19 treatment based on the monoclonal antibody sotrovimab, developed by the British laboratory GSK and the American biotech Vir Biotechnology.